US Neurology Editorial Board member, Jeffrey Cummings (UNVL Department of Brain Health and Cleveland Clinic Lou Ruvo Center for Brain Health, California, USA), considers both successes and failures with emerging new treatments for Alzheimer’s disease, and important steps to be taken to improve future clinical trial design.
1. What is the current status of the clinical development of monoclonal antibodies (mAbs) against the amyloid-β peptide? (0:04)
2. What is the rationale for repurposing drugs such as rasagiline in Alzheimer’s disease (AD)? (1:20)
3. What makes rasagiline particularly attractive as a potential AD treatment? (1:55)
4. What are the current unmet needs in AD research? (2:31)
5. Given the clinical trial failures in AD, how can we improve clinical trial design in the future? (3:23)
Speaker disclosures: Dr Cummings has provided consultation to Acadia, Accera, Actinogen, AgeneBio, Alkahest, Allergan, Alzheon, Avanir, Axsome, Binomics, BiOasis Technologies, Biogen, Bracket, Denali, Diadem, EIP Pharma, Eisai, Genentech, Green Valley, Grifols, Hisun, Idorsia, Lundbeck, MedAvante, Merck, Otsuka, Pain Therapeutics, Probiodrug, Proclara, QR, Resverlogix, Roche, Samumed, Shinkei Therapeutics, Sunovion, Suven, Takeda, and United Neuroscience pharmaceutical and assessment companies. He has also provided consultation to Global Alzheimer Platform (GAP). Dr Cummings owns the copyright of the Neuropsychiatric Inventory (NPl) and is the Chief Scientific Officer of CNS Innovations. He owns stock in ADAMAS, BioAsis, MedAvante, and QR Pharma. He receives the following NIH support: COBRE grant # P20GMI09025; TRC-PAD # R01AG053798; DIAGNOSE CTE # UOINS093334.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Marwan Sabbagh: Approval of Aducanumab for Alzheimer’s Disease
It was a great pleasure to meet up with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Las Vegas, NV, USA), to discuss the recent approval of aducanumab for Alzheimer’s Disease. Aducanumab was granted accelerated approval on June 7 2021, by the U.S. Food and Drug Administration (FDA). Questions: Could you give us a brief […]
Claudia Trenkwalder, EAN 2021: REM Sleep Behaviour Disorder and Neurodegeneration
touchNEUROLOGY was joined by Prof. Claudia Trenkwalder (Paracelsus-Elena-Hospital, Kassel Germany, University Medical Center, Goettingen, Germany) to discuss her EAN presentation looking into REM Sleep Behaviour Disorder and the connection with neurodegeneration. The abstract entitled: ‘REM Sleep Behaviour Disorder (RBD): future implications for neurodegenerative disease’ was presented at the 7th Congress of the European Academy of […]
Ivana Rosenzweig, Sleep and Breathing 2021: The Link Between Sleep Apnoea and Dementia
We were delighted to speak with Dr Ivana Rosenzweig (Sleep and Brain Plasticity Centre, King’s College London, London, UK) around her talk on the ‘Link between sleep apnoea and dementia: the neuroimaging perspective‘, which was presented at the virtual 2021 Sleep and Breathing Conference, 16-17 April, 2021. Questions What is known about the relationship between […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!